CD82 and prostate cancer: Additionally, as in the KAI1 re‐expressing PC3 prostate cancer cells that showed a suppression of both integrin‐ and ligand‐mediated activation of c‐Met,60 the expression of phospho‐c‐MET was also decreased in the KDIP‐injected metastatic liver nodules (Figure 7D).